Paper7650671
Vinyl sulfones as mechanism-based cysteine protease inhibitors.
Palmer JT and 3 others. J Med Chem, 1995. Cited by 400 papers, by iCite.
Cite this record
ConductScience Library. Vinyl sulfones as mechanism-based cysteine protease inhibitors. Papers, record 7650671. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7650671
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cysteine Proteinase Inhibitors | Major topic |
| Sulfones | Major topic |
| Amino Acid Sequence | |
| Drug Design | |
| Kinetics | |
| Molecular Sequence Data |
Source PubMed
Cited by121
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 400 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42704525 | Development and preclinical evaluation of selective vinyl sulfone-based probes for PET imaging of tumor-associated cathepsins. | EJNMMI Radiopharm Chem | 2026 | https://conductscience.org/library/papers/42704525 | PubMed |
| 42381118 | Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids. | J Med Chem | 2026 | https://conductscience.org/library/papers/42381118 | PubMed |
| 41155577 | A Second Opportunity for the Peptide-Based Analogues with γ-Lactam at the P1 Position: Human Cathepsin S Inhibition. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41155577 | PubMed |
| 41022736 | Proteolytic activities of extracellular vesicles attenuate A-synuclein aggregation. | NPJ Parkinsons Dis | 2025 | https://conductscience.org/library/papers/41022736 | PubMed |
| 40739688 | Organosulfur Compounds: Potential Therapeutics for Parkinson's Disease. | CNS Neurol Disord Drug Targets | 2026 | https://conductscience.org/library/papers/40739688 | PubMed |
| 40278767 | Combating Malaria: Targeting the Ubiquitin-Proteasome System to Conquer Drug Resistance. | Trop Med Infect Dis | 2025 | https://conductscience.org/library/papers/40278767 | PubMed |
| 40151260 | Development and Application of Small Molecule-Peptide Conjugates as Cathepsin K-Specific Covalent Irreversible Inhibitors in Human Osteoclast and Lung Cancer. | JACS Au | 2025 | https://conductscience.org/library/papers/40151260 | PubMed |
| 39311309 | Advances in Cathepsin S Inhibition: Challenges and Breakthroughs in Drug Development. | Pathophysiology | 2024 | https://conductscience.org/library/papers/39311309 | PubMed |
| 39236162 | Palladium-catalyzed cross-coupling of alcohols with olefins by positional tuning of a counteranion. | Science | 2024 | https://conductscience.org/library/papers/39236162 | PubMed |
| 39157084 | Clickable Probes for Pathogen Proteasomes: Synthesis and Applications. | ACS Omega | 2024 | https://conductscience.org/library/papers/39157084 | PubMed |
| 38384945 | Flavin-Mediated Photocatalysis Provides a General Platform for Sulfide C-H Functionalization. | ACS Catal | 2024 | https://conductscience.org/library/papers/38384945 | PubMed |
| 37921174 | Targeting SmCB1: Perspectives and Insights to Design Antischistosomal Drugs. | Curr Med Chem | 2024 | https://conductscience.org/library/papers/37921174 | PubMed |
| 37857662 | Mechanistic insights into excited-state palladium catalysis for C-S bond formations and dehydrogenative sulfonylation of amines. | Nat Commun | 2023 | https://conductscience.org/library/papers/37857662 | PubMed |
| 37498810 | Advances in new target molecules against schistosomiasis: A comprehensive discussion of physiological structure and nutrient intake. | PLoS Pathog | 2023 | https://conductscience.org/library/papers/37498810 | PubMed |
| 37443395 | Molecular basis for ubiquitin/Fubi cross-reactivity in USP16 and USP36. | Nat Chem Biol | 2023 | https://conductscience.org/library/papers/37443395 | PubMed |
| 36867428 | Dipeptide-Derived Alkynes as Potent and Selective Irreversible Inhibitors of Cysteine Cathepsins. | J Med Chem | 2023 | https://conductscience.org/library/papers/36867428 | PubMed |
| 35955599 | An Overview of NRF2-Activating Compounds Bearing α,β-Unsaturated Moiety and Their Antioxidant Effects. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35955599 | PubMed |
| 35883746 | The Role of Organosulfur Compounds as Nrf2 Activators and Their Antioxidant Effects. | Antioxidants (Basel) | 2022 | https://conductscience.org/library/papers/35883746 | PubMed |
| 35852812 | Two Tags in One Probe: Combining Fluorescence- and Biotin-based Detection of the Trypanosomal Cysteine Protease Rhodesain. | Chemistry | 2022 | https://conductscience.org/library/papers/35852812 | PubMed |
| 35002435 | Exploring the role of cathepsin in rheumatoid arthritis. | Saudi J Biol Sci | 2022 | https://conductscience.org/library/papers/35002435 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7650671
GET https://conductscience.org/api/papers/v1/7650671/cited_by?page=2